Mark Lewis: Dr. Andrew Ko’s observation at ASCO23 that orders of magnitude separate the cost of NALIRIFOX vs FOLFIRINOX!

Mark Lewis shared on X:

“Seems relevant to resurface Dr. Andrew Ko’s observation at ASCO23 that orders of magnitude separate the cost of NALIRIFOX vs FOLFIRINOX!”

Source: Mark Lewis/X

Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent & young adult (AYA) oncology in the SWOG cooperative group and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.